Trial Profile
Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lutropin alfa (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Therapeutic Use
- 22 Nov 2020 Status changed from recruiting to completed.
- 01 Aug 2014 New trial record